Whole Blood–based Transcriptional Risk Score for Nonobese Type 2 Diabetes Predicts Dynamic Changes in Glucose Metabolism
Main finding · Nonobese T2D riskResult — go to the resultFold higher risk 8.91 95% CI 3.53–22.5Authors' conclusion
A whole blood-based nonobese T2D-associated transcriptional risk score was validated to predict dynamic changes in glucose metabolism. These findings suggested several biological pathways involved in the pathogenesis of nonobese T2D.
Study context
- Population
- Community-based adults aged ≥40 years who maintained a normal body mass index (BMI) for up to 10 years, with blood transcriptome datadevelopment cohort
- Participants
- 1,105 adults
- Exposure
- wb-TRS tertile 3 vs lowest tertile
- Outcome
- Risk of nonobese T2D
Methodological detailscommunity-based, external validation
- Community-based
- External validation
Main finding
Nonobese T2D risk
Fold higher risk
8.91
95% CI 3.53–22.5
As reported in the abstract
- Each 1-unit wb-TRS increment: fold higher risk of nonobese T2D
- 2.63 (95% CI 1.87-3.68)
- wb-TRS gene transcripts
- 144
Observational data: associations, not effects.
Further findings
Dynamic changes in glucose metabolism by CGM · 6 months of intervention
- Baseline wb-TRS significantly associated with changes in average, daytime, nighttime and 24-hour glucose, HbA1c and AUC of glucose
Prediction performance
- wb-TRS improved prediction of nonobese T2D combined with fasting glucose, TG, demographic and anthropometric parameters
Biological pathways (Mitch analysis)
- Oxidative phosphorylation, mTORC1 signaling and cholesterol metabolism implicated
Original publication
Whole Blood–based Transcriptional Risk Score for Nonobese Type 2 Diabetes Predicts Dynamic Changes in Glucose Metabolism. J Clin Endocrinol Metab. Published 9 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →